Neuro-Oncology AdvancesBioengineeringPeer-reviewed journal article
Cell migration simulator-based biomarkers for glioblastoma
J. J. Hou, M. McMahon, J. N. Sarkaria, C. C. Chen, D. J. Odde
Abstract
Glioblastoma is the most aggressive malignant brain tumor with poor survival due to its invasive nature driven by cell migration, with unclear linkage to transcriptomic information. Here, we applied a physics-based motor-clutch model, a cell migration simulator (CMS), to parameterize the migration of glioblastoma cells and define physical biomarkers on a patient-by-patient basis. We reduced the 11-dimensional parameter space of the CMS into 3D to identify three principal physical parameters that govern cell migration: motor number - describing myosin II activity, clutch number - describing adhesion level, and F-actin polymerization rate. Experimentally, we found that glioblastoma patient-derived (xenograft) (PD(X)) cell lines across mesenchymal (MES), proneural (PN), classical (CL) subtypes and two institutions (N=13 patients) had optimal motility and traction force on stiffnesses around 9.3kPa, with otherwise heterogeneous and uncorrelated motility, traction, and F-actin flow. By contrast, with the CMS parameterization, we found glioblastoma cells consistently had balanced motor/clutch ratios to enable effective migration, and that MES cells had higher actin polymerization rates resulting in higher motility. The CMS also predicted differential sensitivity to cytoskeletal drugs between patients. Finally, we identified 11 genes that correlated with the physical parameters, suggesting that transcriptomic data alone could potentially predict the mechanics and speed of glioblastoma cell migration. Overall, we describe a general physics-based framework for parameterizing individual glioblastoma patients and connecting to clinical transcriptomic data, that can potentially be used to develop patient-specific anti-migratory therapeutic strategies generally. Significance StatementSuccessful precision medicine requires biomarkers to define patient states and identify personalized treatments. While biomarkers are generally based on expression levels of protein and/or RNA, we ultimately seek to alter fundamental cell behaviors such as cell migration, which drives tumor invasion and metastasis. Our study defines a new approach for using biophysics-based models to define mechanical biomarkers that can be used to identify patient-specific anti-migratory therapeutic strategies.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Glioblastoma cells use an integrin- and CD44-mediated motor-clutch mode of migration in brain tissue
S. M. Anderson, M. Kelly, D. J. Odde·bioRxiv·Oct 23, 2023
- Spatial heterogeneity of cell-matrix adhesive forces predicts human glioblastoma migration
R. Rezk, B. Z. Jia, … K. Franze·Neuro-Oncology AdvancesPeer-reviewed·Jul 3, 2020
- Mechanical polarity links adhesion-tuned protrusions to directional stability in glioblastoma cell migration
Haruna Tagawa, Daisuke Kanematsu, … Yuichi Sakumura·bioRxiv·Oct 23, 2025
- Differential migration mechanics and immune responses of glioblastoma subtypes
G. A. Shamsan, C. J. Liu, … D. J. Odde·bioRxiv·Jun 26, 2022
- From Single-Cell Emergent Behaviors to Clinical Outcome: PTEN-driven Migratory Efficiency as a Potential New Vulnerability in Glioblastoma
Mariangela Morelli, Gianmarco Ferri, … Chiara Maria Mazzanti·bioRxiv·Mar 20, 2026
- Ex vivo glioblastoma migration phenotypes define clinical recurrence and tumor heterogeneity
Jay Hou, Mariah M. McMahon, … David J. Odde·bioRxiv·Sep 2, 2026